Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs - Real World Outcomes
Published in: Drugs - Real World Outcomes 2/2016

Open Access 01-06-2016 | Original Research Article

Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients

Authors: Annika Hilgers, Marion Schaefer

Published in: Drugs - Real World Outcomes | Issue 2/2016

Login to get access

Abstract

Background

Based on data of clinical trials, new agents are receiving approval to the pharmaceutical market, for which information concerning safety issues under real-life conditions is not yet available.

Objectives

The aim was to evaluate the tolerability of newer antiepileptic drugs (AEDs), such as topiramate, levetiracetam, zonisamide, pregabalin, extended-release oxcarbazepine, lacosamide and eslicarbazepine, under real-life conditions by means of an assessment of routine clinical data of inpatients.

Method

Over 2.75 years data of all inpatients receiving one of the newer AEDs were documented. Occurring adverse drug reactions (ADRs) were classified according to the WHO-UMC Causality Assessment concerning their likely relationship to the prescribed AEDs. For each AED, the total number of patients without and with ADRs, assessed as at least possibly related to the particular drug, was calculated and corresponding incidences compared with reference data provided in the Summary of Product Characteristics (SmPC). For statistical evaluation Spearman correlation (r s), estimated relative risk and logistic regression analysis were used.

Results

In total, the data of 562 patients were assessed, of which 90 % received up to six different AEDs. The proportion of off-label use with regard to dosage varied between 6.4 and 64.7 %. Levetiracetam and oxcarbazepine as an extended-release formulation were most commonly used, and levetiracetam showed the best tolerance. By using logistic regression, the occurrence of ADRs was significantly associated with the number of AEDs (p < 0.001) as well as the defined daily doses (p = 0.003). In total, ADRs of AEDs were documented for 318 patients (56.6 %). The most common referred to electrolyte imbalance, e.g., low sodium (n = 79, 14.1 %) and potassium (n = 25, 4.4 %) levels, the central nervous system, including dizziness (n = 61, 10.9 %), disturbed vision (n = 47, 8.4 %), fatigue (n = 40, 7.1 %), nystagmus (n = 36, 6.4 %) and ataxia (n = 29, 5.2 %), or cognitive deficits, especially disturbance of speech (n = 37, 6.6 %), memory impairment (n = 36, 6.4 %) and mental slowing (n = 32, 5.7 %). By comparing the assessed ADR incidences with specification data, for some ADRs, a probable underestimation by the SmPC of respective risk could be assumed.

Conclusion

During inpatient treatment, valuable data are generated, which are currently rarely utilized for pharmacoepidemiologic or pharmacovigilance purposes. A systematic evaluation of these data can increase the probability of detecting ADRs and can promote real-life–related drug surveillance.
Appendix
Available only for authorised users
Literature
1.
2.
Waller PC, Bahri P. Regulatory pharmacovgilance in the EU. In: Mann RD, Andrews E, editors. Pharmacovigilance. Chichester: Wiley; 2002. p. 183–94.CrossRef
3.
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.CrossRefPubMed
4.
Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.CrossRefPubMed
5.
van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med. 2002;21(14):2027–44.CrossRefPubMed
6.
Gilliam FG. Optimizing health outcomes in active epilepsy. Neurology. 2002;58(Suppl. 5):9–19.CrossRef
7.
8.
Sander JW. Ultimate success in epilepsy—the patient’s perspective. Eur J Neurol. 2005;12(Suppl. 4):3–11.CrossRefPubMed
9.
Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol. 2008;28(3):317–27.CrossRefPubMed
10.
Alexandre V Jr, Capovilla G, Fattore C, Franco V, Gambardella A, Guerrini R, La Briola F, Ladogana M, Rosati E, Specchio LM, Striano S, Perucca E, SOPHIE Study Group. Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia. 2010;51(5):921–5.CrossRefPubMed
11.
Fisher RS, Vickrey BG, Gibson P, Hermann B, Penovich P, Scherer A, Walker S. The impact of epilepsy from the patient’s perspective. Descriptions and subjective perceptions. Epilepsy Res. 2000;41(1):39–51.CrossRefPubMed
12.
Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of antiepileptic drug at a referral centre for epilepsy. Seizure. 2007;16:356–64.
13.
Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51–9.
14.
Johannessen Landmark C, Johannessen SI. Safety aspects of antiepileptic drugs—focus on pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21:11–20.
15.
Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik I, Tomson T, Perucca E. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76.CrossRefPubMed
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T, For the ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.
27.
28.
Cramer JA, Steinborn B, Striano P, Hlinkova L, Bergmann A, Bacos I, Baukens C, Buyle S. Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand. 2011;124(1):13–21.CrossRefPubMed
29.
Fritze J. Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2011. Psychopharmakotherapie. 2011;18:245–56.
30.
Malerba A, Ciampa C, De Fazio S, Fattore C, Frassine B, La Neve A, Pellacani S, Specchio LM, Tiberti A, Tinuper P, Perucca E. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res. 2010;91:273–82.CrossRefPubMed
31.
Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, and Perucca E, On behalf of the SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51(5):797–804.
32.
33.
Louis EKS. Truly “Rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96–105.CrossRef
34.
Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, van Lier H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia. 1995;36:440–6.CrossRefPubMed
35.
Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000;41:107–39.CrossRefPubMed
36.
Striano S, Striano P, Capone D, Pisanti F. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med Sci Monit. 2008;14(10):173–8.
37.
38.
Baker GA, Camfield C, Camfield P, Cramer JA, Elger CE, Johnson AL, Martins da Silva A, Meinardi H, Munari C, Perucca E, Thorbecke R. Commission on outcome measurement in epilepsy, 1994–1997: final report. Epilepsia. 1998;39(2):213–23.CrossRefPubMed
39.
Franco V, Canevini MP, Capovilla G, De Sarro G, Galimberti CA, Gatti G, Guerrini R, La Neve A, Rosati E, Specchio LM, Striano S, Tinuper P, Perucca E. Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy. CNS Drugs. 2014;28(10):939–49.CrossRefPubMed
40.
Gilliam FD. What we dont’t learn from clinical trials in epilepsy. Epilepsia. 2003;44(Suppl. 7):51–4.CrossRefPubMed
41.
Gilliam FD. Epilepsy—success in clinical practice: translating trials to practice. Eur J Neurol. 2005;12(Suppl. 4):22–9.CrossRefPubMed
42.
Perucca P, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand. 2005;112(Suppl. 181):30–5.CrossRef
43.
Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, Simonetti GD, Ramelli GP, Bianchetti MG, Lava SAG. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. BJCP. 2013;77(6):758–64.
44.
Mirza NS, Alfirevic A, Jorgensen A, Marson AG, Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics. 2011;21:297–302.CrossRefPubMed
45.
Lin CH, Lu CH, Wang FJ, Tsai MH, Chang WN, Tsai NW, Lai SL, Tseng YL, Chuang YC. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clin Neuropharmacol. 2010;33(6):293–6.CrossRefPubMed
46.
Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain. 2015;16:81–7.CrossRefPubMedCentral
47.
Buggy Y, Layton D, Fogg C, Shakir SAW. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia. 2010;51(5):818–29.CrossRefPubMed
48.
Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–8.CrossRefPubMed
49.
Kim YS, Kim DW, Jung KH, Lee ST, Kang BS, Byun JI, Yeom JS, Chu K, Lee SK. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure. 2014;23:208–12.CrossRefPubMed
50.
Ortenzi A, Paggi A, Foschi N, Sabbatini D, Pistoli E. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy. Funct Neurol. 2008;23(2):97–100.PubMed
51.
Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatremia following esclicarbazepine therapy. Seizure. 2015;29:11–4.CrossRefPubMed
52.
Ley M, Principe A, Jiménez-Conde J, Rocamora R. Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests. Epilepsy Res. 2015;115:147–52.CrossRefPubMed
53.
54.
Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14:202–9.CrossRefPubMed
55.
Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res. 2003;54:171–8.CrossRefPubMed
56.
Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17:413–25.CrossRefPubMed
57.
Loring DW, Williamson DJ, Meador KJ, Wiegand F, Hulihan J. Topiramate dose effects on cognition. A randomized double-blind study. Neurology. 2011;76:131–7.CrossRefPubMed
58.
59.
Ojemann LM, Ojemann GA, Dodrill CB, Crawford CA, Holmes MD, Dudley DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav. 2001;2:579–84.CrossRefPubMed
60.
Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, Gates J, Penovich P, Al-Asmi A, Dubeau F, Jones-Gotman M. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44(3):339–47.CrossRefPubMed
61.
Sommer BR, Mitchell EL, Wroolie TE. Topiramate: effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord. 2013;6(4):211–27.CrossRefPubMedPubMedCentral
62.
63.
64.
65.
66.
67.
Metadata
Title
Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients
Authors
Annika Hilgers
Marion Schaefer
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Drugs - Real World Outcomes / Issue 2/2016
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI
https://doi.org/10.1007/s40801-016-0077-2

Other articles of this Issue 2/2016

Drugs - Real World Outcomes 2/2016 Go to the issue

Original Research Article

Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study

Review Article

The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review

Erratum

Erratum to: Haloperidol Use Among Elderly Patients Undergoing Surgery: A Retrospective 1-Year Study in a Hospital Population

Original Research Article

The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk

Original Research Article

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors

Original Research Article

Survey of Physicians’ Understanding of Specific Risks Associated with Retigabine